



General description

Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat primary immunodeficiency and Kawasaki disease.

ATC codes	J06BA02
Medicine type	Biological agent
EML status history	<p>First added in 1977 (TRS 615) for Primary immunodeficiencies</p> <p>Added in 1977 (TRS 615) for Mucocutaneous lymph node syndrome</p> <p>Removed in 2003 (TRS 920) for Primary immunodeficiencies</p> <p>Removed in 2003 (TRS 920) for Mucocutaneous lymph node syndrome</p> <p>Added in 2007 (TRS 946) for Primary immunodeficiencies</p> <p>Added in 2007 (TRS 946) for Mucocutaneous lymph node syndrome</p> <p>Added in 2023 (TRS 1049) for Langerhans cell histiocytosis</p>
Wikipedia	Normal immunoglobulin
DrugBank	Normal immunoglobulin (Immune Globulin Human)

Recommendations

Section Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

